Breaking Finance News

DexCom, Inc. (NASDAQ:DXCM) has been upgraded to Buy in a statement by BidaskClub earlier today.

BidaskClub has upgraded DexCom, Inc. (NASDAQ:DXCM) to Buy in a statement released on 6/21/2017.

Boasting a price of $78.33, DexCom, Inc. (NASDAQ:DXCM) traded 1.83% higher on the day. With the last stock price close up 1.05% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. DexCom, Inc. has recorded a 50-day average of $72.12 and a two hundred day average of $74.18. Volume of trade was down over the average, with 854,164 shares of DXCM changing hands under the typical 1,187,230

Performance Chart

DexCom, Inc. (NASDAQ:DXCM)

With a total market value of $0, DexCom, Inc. has with a one year low of $57.68 and a one year high of $94.79 .

Brief Synopsis About DexCom, Inc. (NASDAQ:DXCM)

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.